Novartis wins rights to hepatitis drug

Published: 10-Feb-2010
Research & Development Pharmaceutical

To Debiopharm Group\'s Debio 025 (alisporivir) for the treatment of hepatitis


Novartis has won exclusive, worldwide rights to Debiopharm Group's Debio 025 (alisporivir) for the treatment of hepatitis.

Debiopharm has granted Novartis worldwide commercialisation rights, except in Japan.

Under the terms of the agreement, Novartis will pay Swiss biopharmaceutical Debiopharm an upfront payment, development and sales milestones, as well as royalties.

Debio 025 is a selective cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C virus (HCV) effect. The product is currently in phase 2b clinical development for the treatment of hepatitis C.




  • Companies:
  • Debiopharm International
  • Novartis
See more

You may also like

Research & Development

Intellegens secures $2m to support research of oligonucleotide therapeutic manufacture

Read more
In collaboration with CPI, Intellegens has secured a grant from Innovate UK to fund a two year project to augment technology that will assist productivity and yields of oligonucleotide therapeutic manufacture

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. Compact process thermostat for efficient temperature control in the laboratory The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
  3. Prima BioMed announces new product candidate IMP761: a LAG-3 agonist antibody Prima BioMed announces that it has developed a new early stage product candidate, a humanised IgG4 monoclonal antibody to be known as IMP761
  4. Wacker Chemical Corporation promotes Christoph Kowitz to President of US subsidiary The position originally held by David Willhoit is a promotion from Christoph's six year tenure as the Head of Corporate R&D
  5. The colouration of tablets and capsules Paul Smith from Sensient Pharmaceutical Technologies discusses the use of colour in solid oral dosage forms

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Research & Development

Intellegens secures $2m to support research of oligonucleotide therapeutic manufacture

In collaboration with CPI, Intellegens has secured a grant from Innovate UK to fund a two year project to augment technology that will assist productivity and yields of oligonucleotide therapeutic manufacture
Manufacturing

MIT researchers to lead a new centre for continuous mRNA manufacturing

Faculty at the MIT are embarking upon a three-year research programme to design the world's first fully integrated, continuous mRNA manufacturing platform
Drug Delivery

Novartis publishes data on multiple sclerosis treatment

Data showed the sustained efficacy of continuous Kesimpta (ofatumumab) treatment over five years in patients with relapsing forms of multiple sclerosis (RMS)
Research & Development

Novartis and MMV move to Phase III study to treat uncomplicated malaria

As the world faces emerging resistance to current malaria treatments, new medicines are needed to continue the fight toward elimination
Ingredients

Therapeutic: inclisiran for hypercholesterolaemia

The importance of managing low-density lipoprotein cholesterol (LDL-C) levels in cardiovascular disease is well recognised, with cholesterol lowering drugs such as statins being routinely prescribed to those at risk
Research & Development

Novartis to fund protein degrader therapy research

Novartis has an exclusive option to develop and commercialise products resulting from the research programs directed against up to four drug targets
Manufacturing

Novartis opens facility for innovative cell and gene therapies in Switzerland

New building in Stein also hosts the production of difficult-to-manufacture solid dosage forms
Subscribe now